Difference between revisions of "Osteosarcoma, pediatric"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
Line 50: Line 50:
 
#'''COG AOST0331:''' Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Krailo MD, Hook JM, Arndt C, Berg H, Brennan B, Brichard B, Brown KLB, Butterfass-Bahloul T, Calaminus G, Daldrup-Link HE, Eriksson M, Gebhardt MC, Gelderblom H, Gerss J, Goldsby R,  Goorin A, Gorlick R, Grier H, Hale JP, Hall KS, Hardes J, Hawkins DS, Helmke K, Hogendoorn PCW, Isakoff MS, JAneway KA, Jurgens H, Kager L, Kuhne T, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Meyers PA, Mottl H, Nathrath M, Papai Z, Randall RL, Reichardt P, Renard M, Safwat AA, Schwartz CL, Stevens MCG, Strauss SJ, Teot L, Werner M, Sydes MR, Whelan JS. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international randomized controlled trial. J Clin Oncol. 2020 Feb 20;38(6):602-612. Epub 2019 Dec 11. [https://doi.org/10.1016/s1470-2045(16)30214-5 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5052459/ link to PMC article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/27569442/ PubMed] NCT00134030
 
#'''COG AOST0331:''' Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Krailo MD, Hook JM, Arndt C, Berg H, Brennan B, Brichard B, Brown KLB, Butterfass-Bahloul T, Calaminus G, Daldrup-Link HE, Eriksson M, Gebhardt MC, Gelderblom H, Gerss J, Goldsby R,  Goorin A, Gorlick R, Grier H, Hale JP, Hall KS, Hardes J, Hawkins DS, Helmke K, Hogendoorn PCW, Isakoff MS, JAneway KA, Jurgens H, Kager L, Kuhne T, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Meyers PA, Mottl H, Nathrath M, Papai Z, Randall RL, Reichardt P, Renard M, Safwat AA, Schwartz CL, Stevens MCG, Strauss SJ, Teot L, Werner M, Sydes MR, Whelan JS. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international randomized controlled trial. J Clin Oncol. 2020 Feb 20;38(6):602-612. Epub 2019 Dec 11. [https://doi.org/10.1016/s1470-2045(16)30214-5 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5052459/ link to PMC article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/27569442/ PubMed] NCT00134030
  
−
=COG AOST0331 MAPifn Group=
+
=Relapsed Refractory=
−
==Induction==
 
−
Received by all patients and consists of 2 cycles of MAP.
 
−
===Chemotherapy===
 
−
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV infusion over 4 hours, started on day 1 of weeks 1 and 6
 
−
*[[Doxorubicin (Adriamycin)]] 37.5 mg/m<sup>2</sup>/day (total dose is 75 mg/m<sup>2</sup> given as a 48 hour infusion) on days 1 to 2 of Weeks 1 and 6
 
−
*[[Methotrexate (MTX)]] 12 g/m<sup>2</sup> (MAX DOSE = 20 grams) IV over 4 hours once on day 1 of weeks 4, 5, 9, and 10.
 
−
*[[Folinic acid (Leucovorin)]] 15 mg/m<sup>2</sup> PO or IV every 6 hours beginning 24 hours after the beginning of the [[Methotrexate (MTX)]] infusion and continuing until the serum [[Methotrexate (MTX)]] level is less than 0.1 μM.
 
−
 
 
−
'''10 Week Course'''
 
−
 
 
−
===References===
 
−
#'''COG AOST0331:''' Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Krailo MD, Hook JM, Arndt C, Berg H, Brennan B, Brichard B, Brown KLB, Butterfass-Bahloul T, Calaminus G, Daldrup-Link HE, Eriksson M, Gebhardt MC, Gelderblom H, Gerss J, Goldsby R,  Goorin A, Gorlick R, Grier H, Hale JP, Hall KS, Hardes J, Hawkins DS, Helmke K, Hogendoorn PCW, Isakoff MS, JAneway KA, Jurgens H, Kager L, Kuhne T, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Meyers PA, Mottl H, Nathrath M, Papai Z, Randall RL, Reichardt P, Renard M, Safwat AA, Schwartz CL, Stevens MCG, Strauss SJ, Teot L, Werner M, Sydes MR, Whelan JS. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international randomized controlled trial. J Clin Oncol. 2020 Feb 20;38(6):602-612. Epub 2019 Dec 11. [https://doi.org/10.1016/s1470-2045(16)30214-5 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5052459/ link to PMC article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/27569442/ PubMed] NCT00134030
 
−
 
 
−
==MAPifn Cycles 3-4==
 
−
Good Responders
 
−
 
 
−
===Chemotherapy===
 
−
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV infusion over 4 hours, started on day 1 of weeks 12 and 17
 
−
*[[Doxorubicin (Adriamycin)]] 37.5 mg/m<sup>2</sup>/day (total dose is 75 mg/m<sup>2</sup> given as a 48 hour infusion) on days 1 to 2 of Weeks 12 and 17.
 
−
*[[Methotrexate (MTX)]] 12 g/m<sup>2</sup> (MAX DOSE = 20 grams) IV over 4 hours once on day 1 of weeks 15, 16, 20, and 21.
 
−
*[[Folinic acid (Leucovorin)]] 15 mg/m<sup>2</sup> PO or IV every 6 hours beginning 24 hours after the beginning of the [[Methotrexate (MTX)]] infusion and continuing until the serum [[Methotrexate (MTX)]] level is less than 0.1 μM.
 
−
 
 
−
'''10 Week Course'''
 
−
 
 
−
===References===
 
−
#'''COG AOST0331:''' Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Krailo MD, Hook JM, Arndt C, Berg H, Brennan B, Brichard B, Brown KLB, Butterfass-Bahloul T, Calaminus G, Daldrup-Link HE, Eriksson M, Gebhardt MC, Gelderblom H, Gerss J, Goldsby R,  Goorin A, Gorlick R, Grier H, Hale JP, Hall KS, Hardes J, Hawkins DS, Helmke K, Hogendoorn PCW, Isakoff MS, JAneway KA, Jurgens H, Kager L, Kuhne T, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Meyers PA, Mottl H, Nathrath M, Papai Z, Randall RL, Reichardt P, Renard M, Safwat AA, Schwartz CL, Stevens MCG, Strauss SJ, Teot L, Werner M, Sydes MR, Whelan JS. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international randomized controlled trial. J Clin Oncol. 2020 Feb 20;38(6):602-612. Epub 2019 Dec 11. [https://doi.org/10.1016/s1470-2045(16)30214-5 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5052459/ link to PMC article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/27569442/ PubMed] NCT00134030
 
−
 
 
−
==MAPifn Cycles 5-6==
 
−
Good Responders
 
−
 
 
−
===Chemotherapy===
 
−
*[[Doxorubicin (Adriamycin)]] 37.5 mg/m<sup>2</sup>/day (total dose is 75 mg/m<sup>2</sup> given as a 48 hour infusion) on days 1 to 2 of Weeks 22 and 26.
 
−
*[[Methotrexate (MTX)]] 12 g/m<sup>2</sup> (MAX DOSE = 20 grams) IV over 4 hours once on day 1 of weeks 24, 25, 28, and 29.
 
−
*[[Folinic acid (Leucovorin)]] 15 mg/m<sup>2</sup> PO or IV every 6 hours beginning 24 hours after the beginning of the [[Methotrexate (MTX)]] infusion and continuing until the serum [[Methotrexate (MTX)]] level is less than 0.1 μM.
 
−
 
 
−
'''10 Week Course'''
 
−
 
 
−
===References===
 
−
#'''COG AOST0331:''' Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Krailo MD, Hook JM, Arndt C, Berg H, Brennan B, Brichard B, Brown KLB, Butterfass-Bahloul T, Calaminus G, Daldrup-Link HE, Eriksson M, Gebhardt MC, Gelderblom H, Gerss J, Goldsby R,  Goorin A, Gorlick R, Grier H, Hale JP, Hall KS, Hardes J, Hawkins DS, Helmke K, Hogendoorn PCW, Isakoff MS, JAneway KA, Jurgens H, Kager L, Kuhne T, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Meyers PA, Mottl H, Nathrath M, Papai Z, Randall RL, Reichardt P, Renard M, Safwat AA, Schwartz CL, Stevens MCG, Strauss SJ, Teot L, Werner M, Sydes MR, Whelan JS. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international randomized controlled trial. J Clin Oncol. 2020 Feb 20;38(6):602-612. Epub 2019 Dec 11. [https://doi.org/10.1016/s1470-2045(16)30214-5 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5052459/ link to PMC article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/27569442/ PubMed] NCT00134030
 
−
 
 
−
==MAPifn Weeks 30-104==
 
−
Good Responders
 
−
===Chemotherapy===
 
−
*[[Peginterferon alfa-2b (PegIntron)]] 0.5 μg/kg/day (MAX DOSE = 50 μg) subcutaneously on day 1 of Weeks 30, 31, 32, and 33.
 
−
**If well tolerated during first 4 weeks of therapy, escalate dose.
 
−
*[[Peginterferon alfa-2b (PegIntron)]] 1 μg/kg/day (MAX DOSE = 100 μg) subcutaneously on day 1 of Weeks 34 through 104.
 
−
 
 
−
'''75 Week Course'''
 
−
 
 
−
===References===
 
−
#'''COG AOST0331:''' Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Krailo MD, Hook JM, Arndt C, Berg H, Brennan B, Brichard B, Brown KLB, Butterfass-Bahloul T, Calaminus G, Daldrup-Link HE, Eriksson M, Gebhardt MC, Gelderblom H, Gerss J, Goldsby R,  Goorin A, Gorlick R, Grier H, Hale JP, Hall KS, Hardes J, Hawkins DS, Helmke K, Hogendoorn PCW, Isakoff MS, JAneway KA, Jurgens H, Kager L, Kuhne T, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Meyers PA, Mottl H, Nathrath M, Papai Z, Randall RL, Reichardt P, Renard M, Safwat AA, Schwartz CL, Stevens MCG, Strauss SJ, Teot L, Werner M, Sydes MR, Whelan JS. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international randomized controlled trial. J Clin Oncol. 2020 Feb 20;38(6):602-612. Epub 2019 Dec 11. [https://doi.org/10.1016/s1470-2045(16)30214-5 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5052459/ link to PMC article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/27569442/ PubMed] NCT00134030
 
−
 
 
−
=COG AOST0331 MAPIE Group=
 
−
==Induction==
 
−
Received by all patients and consists of 2 cycles of MAP.
 
−
===Chemotherapy===
 
−
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV infusion over 4 hours, started on day 1 of weeks 1 and 6
 
−
*[[Doxorubicin (Adriamycin)]] 37.5 mg/m<sup>2</sup>/day (total dose is 75 mg/m<sup>2</sup> given as a 48 hour infusion) on days 1 to 2 of Weeks 1 and 6
 
−
*[[Methotrexate (MTX)]] 12 g/m<sup>2</sup> (MAX DOSE = 20 grams) IV over 4 hours once on day 1 of weeks 4, 5, 9, and 10.
 
−
*[[Folinic acid (Leucovorin)]] 15 mg/m<sup>2</sup> PO or IV every 6 hours beginning 24 hours after the beginning of the [[Methotrexate (MTX)]] infusion and continuing until the serum [[Methotrexate (MTX)]] level is less than 0.1 μM.
 
−
 
 
−
'''10 Week Course'''
 
−
 
 
−
===References===
 
−
#'''COG AOST0331:''' Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Krailo MD, Hook JM, Arndt C, Berg H, Brennan B, Brichard B, Brown KLB, Butterfass-Bahloul T, Calaminus G, Daldrup-Link HE, Eriksson M, Gebhardt MC, Gelderblom H, Gerss J, Goldsby R,  Goorin A, Gorlick R, Grier H, Hale JP, Hall KS, Hardes J, Hawkins DS, Helmke K, Hogendoorn PCW, Isakoff MS, JAneway KA, Jurgens H, Kager L, Kuhne T, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Meyers PA, Mottl H, Nathrath M, Papai Z, Randall RL, Reichardt P, Renard M, Safwat AA, Schwartz CL, Stevens MCG, Strauss SJ, Teot L, Werner M, Sydes MR, Whelan JS. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international randomized controlled trial. J Clin Oncol. 2020 Feb 20;38(6):602-612. Epub 2019 Dec 11. [https://doi.org/10.1016/s1470-2045(16)30214-5 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5052459/ link to PMC article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/27569442/ PubMed] NCT00134030
 
−
 
 
−
==MAPIE Cycles 3 and 7==
 
−
Poor Responders
 
−
 
 
−
===Chemotherapy===
 
−
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV infusion over 4 hours, started on day 1 of weeks 12 and 28
 
−
*[[Doxorubicin (Adriamycin)]] 37.5 mg/m<sup>2</sup>/day (total dose is 75 mg/m<sup>2</sup> given as a 48 hour infusion) on days 1 to 2 of Weeks 12 and 28.
 
−
*[[Methotrexate (MTX)]] 12 g/m<sup>2</sup> (MAX DOSE = 20 grams) IV over 4 hours once on day 1 of weeks 15 and 31.
 
−
*[[Folinic acid (Leucovorin)]] 15 mg/m<sup>2</sup> PO or IV every 6 hours beginning 24 hours after the beginning of the [[Methotrexate (MTX)]] infusion and continuing until the serum [[Methotrexate (MTX)]] level is less than 0.1 μM.
 
−
 
 
−
'''5-Week Courses'''
 
−
 
 
−
===References===
 
−
#'''COG AOST0331:''' Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Krailo MD, Hook JM, Arndt C, Berg H, Brennan B, Brichard B, Brown KLB, Butterfass-Bahloul T, Calaminus G, Daldrup-Link HE, Eriksson M, Gebhardt MC, Gelderblom H, Gerss J, Goldsby R,  Goorin A, Gorlick R, Grier H, Hale JP, Hall KS, Hardes J, Hawkins DS, Helmke K, Hogendoorn PCW, Isakoff MS, JAneway KA, Jurgens H, Kager L, Kuhne T, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Meyers PA, Mottl H, Nathrath M, Papai Z, Randall RL, Reichardt P, Renard M, Safwat AA, Schwartz CL, Stevens MCG, Strauss SJ, Teot L, Werner M, Sydes MR, Whelan JS. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international randomized controlled trial. J Clin Oncol. 2020 Feb 20;38(6):602-612. Epub 2019 Dec 11. [https://doi.org/10.1016/s1470-2045(16)30214-5 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5052459/ link to PMC article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/27569442/ PubMed] NCT00134030
 
−
 
 
−
==MAP Cycles 4, 6, and 8==
 
−
Poor Responders
 
−
 
 
−
===Chemotherapy===
 
−
*[[Ifosfamide (Ifex)]] 2.8 g/m<sup>2</sup>/dose IV over 4 hours once per day on days 1 through 5 of weeks 16, 24, and 32.
 
−
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup>/dose IV over 60 minutes once per day on days 1 through 5 of weeks 16, 24, and 32.
 
−
*[[Mesna (Mesnex)]] 2.8 g/m<sup>2</sup>/24 hours IV continuous infusion over 24 hours on days 1 through 5 of weeks 16, 24, and 32.
 
−
*[[Methotrexate (MTX)]] 12 g/m<sup>2</sup> (MAX DOSE = 20 grams) IV over 4 hours once on day 1 of weeks 19, 27, and 35.
 
−
*[[Folinic acid (Leucovorin)]] 15 mg/m<sup>2</sup> PO or IV every 6 hours beginning 24 hours after the beginning of the [[Methotrexate (MTX)]] infusion and continuing until the serum [[Methotrexate (MTX)]] level is less than 0.1 μM.
 
−
 
 
−
'''5-Week Courses'''
 
−
 
 
−
===References===
 
−
#'''COG AOST0331:''' Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Krailo MD, Hook JM, Arndt C, Berg H, Brennan B, Brichard B, Brown KLB, Butterfass-Bahloul T, Calaminus G, Daldrup-Link HE, Eriksson M, Gebhardt MC, Gelderblom H, Gerss J, Goldsby R,  Goorin A, Gorlick R, Grier H, Hale JP, Hall KS, Hardes J, Hawkins DS, Helmke K, Hogendoorn PCW, Isakoff MS, JAneway KA, Jurgens H, Kager L, Kuhne T, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Meyers PA, Mottl H, Nathrath M, Papai Z, Randall RL, Reichardt P, Renard M, Safwat AA, Schwartz CL, Stevens MCG, Strauss SJ, Teot L, Werner M, Sydes MR, Whelan JS. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international randomized controlled trial. J Clin Oncol. 2020 Feb 20;38(6):602-612. Epub 2019 Dec 11. [https://doi.org/10.1016/s1470-2045(16)30214-5 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5052459/ link to PMC article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/27569442/ PubMed] NCT00134030
 
−
 
 
−
==MAP Cycle 5==
 
−
Poor Responders
 
−
 
 
−
===Chemotherapy===
 
−
*[[Doxorubicin (Adriamycin)]] 37.5 mg/m<sup>2</sup>/day (total dose is 75 mg/m<sup>2</sup> given as a 48 hour infusion) on days 1 to 2 of Week 20.
 
−
*[[Ifosfamide (Ifex)]] 3 g/m<sup>2</sup>/dose IV over 4 hours once per day on days 1, 2, and 3 of weeks 20.
 
−
*[[Mesna (Mesnex)]] 3 g/m<sup>2</sup>/24 hours IV continuous infusion over 24 hours on days 1, 2, and 3 of weeks 20.
 
−
*[[Methotrexate (MTX)]] 12 g/m<sup>2</sup> (MAX DOSE = 20 grams) IV over 4 hours once on day 1 of weeks 23.
 
−
*[[Folinic acid (Leucovorin)]] 15 mg/m<sup>2</sup> PO or IV every 6 hours beginning 24 hours after the beginning of the [[Methotrexate (MTX)]] infusion and continuing until the serum [[Methotrexate (MTX)]] level is less than 0.1 μM.
 
−
 
 
−
'''5-Week Courses'''
 
−
 
 
−
===References===
 
−
#'''COG AOST0331:''' Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Krailo MD, Hook JM, Arndt C, Berg H, Brennan B, Brichard B, Brown KLB, Butterfass-Bahloul T, Calaminus G, Daldrup-Link HE, Eriksson M, Gebhardt MC, Gelderblom H, Gerss J, Goldsby R,  Goorin A, Gorlick R, Grier H, Hale JP, Hall KS, Hardes J, Hawkins DS, Helmke K, Hogendoorn PCW, Isakoff MS, JAneway KA, Jurgens H, Kager L, Kuhne T, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Meyers PA, Mottl H, Nathrath M, Papai Z, Randall RL, Reichardt P, Renard M, Safwat AA, Schwartz CL, Stevens MCG, Strauss SJ, Teot L, Werner M, Sydes MR, Whelan JS. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international randomized controlled trial. J Clin Oncol. 2020 Feb 20;38(6):602-612. Epub 2019 Dec 11. [https://doi.org/10.1016/s1470-2045(16)30214-5 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5052459/ link to PMC article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/27569442/ PubMed] NCT00134030
 
−
 
 
−
==MAP Cycle 9==
 
−
Poor Responders
 
−
 
 
−
===Chemotherapy===
 
−
*[[Doxorubicin (Adriamycin)]] 37.5 mg/m<sup>2</sup>/day (total dose is 75 mg/m<sup>2</sup> given as a 48 hour infusion) on days 1 to 2 of Week 36.
 
−
*[[Ifosfamide (Ifex)]] 3 g/m<sup>2</sup>/dose IV over 4 hours once per day on days 1, 2, and 3 of weeks 36.
 
−
*[[Mesna (Mesnex)]] 3 g/m<sup>2</sup>/24 hours IV continuous infusion over 24 hours on days 1, 2, and 3 of weeks 36.
 
−
*[[Methotrexate (MTX)]] 12 g/m<sup>2</sup> (MAX DOSE = 20 grams) IV over 4 hours once on day 1 of weeks 39 and 40.
 
−
*[[Folinic acid (Leucovorin)]] 15 mg/m<sup>2</sup> PO or IV every 6 hours beginning 24 hours after the beginning of the [[Methotrexate (MTX)]] infusion and continuing until the serum [[Methotrexate (MTX)]] level is less than 0.1 μM.
 
−
 
 
−
'''5-Week Courses'''
 
−
 
 
−
===References===
 
−
#'''COG AOST0331:''' Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Krailo MD, Hook JM, Arndt C, Berg H, Brennan B, Brichard B, Brown KLB, Butterfass-Bahloul T, Calaminus G, Daldrup-Link HE, Eriksson M, Gebhardt MC, Gelderblom H, Gerss J, Goldsby R,  Goorin A, Gorlick R, Grier H, Hale JP, Hall KS, Hardes J, Hawkins DS, Helmke K, Hogendoorn PCW, Isakoff MS, JAneway KA, Jurgens H, Kager L, Kuhne T, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Meyers PA, Mottl H, Nathrath M, Papai Z, Randall RL, Reichardt P, Renard M, Safwat AA, Schwartz CL, Stevens MCG, Strauss SJ, Teot L, Werner M, Sydes MR, Whelan JS. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international randomized controlled trial. J Clin Oncol. 2020 Feb 20;38(6):602-612. Epub 2019 Dec 11. [https://doi.org/10.1016/s1470-2045(16)30214-5 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5052459/ link to PMC article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/27569442/ PubMed] NCT00134030
 
  
  

Revision as of 21:48, 3 February 2022

Section editor transclusions


0 regimens on this page
0 variants on this page


COG AOST0331 MAP Group

Induction

Received by all patients and consists of 2 cycles of MAP.

Chemotherapy

10 Week Course

References

  1. COG AOST0331: Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Krailo MD, Hook JM, Arndt C, Berg H, Brennan B, Brichard B, Brown KLB, Butterfass-Bahloul T, Calaminus G, Daldrup-Link HE, Eriksson M, Gebhardt MC, Gelderblom H, Gerss J, Goldsby R, Goorin A, Gorlick R, Grier H, Hale JP, Hall KS, Hardes J, Hawkins DS, Helmke K, Hogendoorn PCW, Isakoff MS, JAneway KA, Jurgens H, Kager L, Kuhne T, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Meyers PA, Mottl H, Nathrath M, Papai Z, Randall RL, Reichardt P, Renard M, Safwat AA, Schwartz CL, Stevens MCG, Strauss SJ, Teot L, Werner M, Sydes MR, Whelan JS. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international randomized controlled trial. J Clin Oncol. 2020 Fe1b 20;38(6):602-62. Epub 2019 Dec 11. link to original article link to PMC article contains verified protocol PubMed NCT00134030

MAP Cycles 3-4

Good Responders and Poor Responders

Chemotherapy

10 Week Course

References

  1. COG AOST0331: Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Krailo MD, Hook JM, Arndt C, Berg H, Brennan B, Brichard B, Brown KLB, Butterfass-Bahloul T, Calaminus G, Daldrup-Link HE, Eriksson M, Gebhardt MC, Gelderblom H, Gerss J, Goldsby R, Goorin A, Gorlick R, Grier H, Hale JP, Hall KS, Hardes J, Hawkins DS, Helmke K, Hogendoorn PCW, Isakoff MS, JAneway KA, Jurgens H, Kager L, Kuhne T, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Meyers PA, Mottl H, Nathrath M, Papai Z, Randall RL, Reichardt P, Renard M, Safwat AA, Schwartz CL, Stevens MCG, Strauss SJ, Teot L, Werner M, Sydes MR, Whelan JS. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international randomized controlled trial. J Clin Oncol. 2020 Feb 20;38(6):602-612. Epub 2019 Dec 11. link to original article link to PMC article contains verified protocol PubMed NCT00134030

MAP Cycles 5-6

Good Responders and Poor Responders

Chemotherapy

10 Week Course

References

  1. COG AOST0331: Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Krailo MD, Hook JM, Arndt C, Berg H, Brennan B, Brichard B, Brown KLB, Butterfass-Bahloul T, Calaminus G, Daldrup-Link HE, Eriksson M, Gebhardt MC, Gelderblom H, Gerss J, Goldsby R, Goorin A, Gorlick R, Grier H, Hale JP, Hall KS, Hardes J, Hawkins DS, Helmke K, Hogendoorn PCW, Isakoff MS, JAneway KA, Jurgens H, Kager L, Kuhne T, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Meyers PA, Mottl H, Nathrath M, Papai Z, Randall RL, Reichardt P, Renard M, Safwat AA, Schwartz CL, Stevens MCG, Strauss SJ, Teot L, Werner M, Sydes MR, Whelan JS. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international randomized controlled trial. J Clin Oncol. 2020 Feb 20;38(6):602-612. Epub 2019 Dec 11. link to original article link to PMC article contains verified protocol PubMed NCT00134030

Relapsed Refractory

Retrieved from "https://hemonc.org/w/index.php?title=Osteosarcoma,_pediatric&oldid=54383"